Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Delivers Growth in All Focus Therapeutic Areas in April-December
February 4, 2022
- Novartis Japan Developing Iptacopan as Priority Product, Initially Targeting 3 Indications
February 4, 2022
- Chugai’s Sales and Profit Rose for 5 Years Running, 1 Trillion Yen-Plus Expected in 2022
February 4, 2022
- Eisai’s April-December Sales Zoom 13.4% on Lenvima Growth Overseas
February 4, 2022
- Takeda’s Osaka Plant Digitized with Cutting Edge Techs to Create Supply System for Its 1st Cell Therapy
February 4, 2022
- 650 Astellas Staffers Choose Voluntary Redundancy, Sales Force Down to 1,200
February 3, 2022
- Astellas Sees Surge in 9-Month Revenue on Xtandi Growth, US Market Recovery
February 3, 2022
- Cariprazine Adds Bipolar Indication in Singapore: Mitsubishi Tanabe
February 3, 2022
- Boehringer to Rejig Japan Sales Offices as Work Style Shifts, No Rep Cut Planned
February 2, 2022
- Sumitomo Dainippon Expects to Get Back on Growth Track in FY2025 after Latuda’s LOE: President
February 2, 2022
- Tau Antibody Licensed to US Merck Enters Clinic: Teijin
February 2, 2022
- Sumitomo Dainippon’s 9-Month Profit Sinks 33.5% on US Promotions, Other Factors
February 1, 2022
- Lenvima/Keytruda Combo Approved in Taiwan for Advanced RCC
February 1, 2022
- Buoyant Opdivo and Forxiga Drive Ono’s Growth in April-December
February 1, 2022
- Daiichi Sankyo Initiates COVID-19 Booster Study in Japan
February 1, 2022
- Kyowa Kirin Files Ophthalmic Mitomycin C Agent in Japan
February 1, 2022
- Oncolys’ Nucleocapsid Inhibitor Effective against Omicron, PI Launch by Year-End
February 1, 2022
- Shionogi’s April-Dec. Operating Profit Tumbles 40%-Plus on Antibiotic Promotion, COVID R&D
February 1, 2022
- Daiichi Sankyo’s Revenue Rises 9.8% in April-December on Upbeat Mainstays
February 1, 2022
- Ivermectin Shows Antiviral Effects against Omicron: Kowa
February 1, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…